1- Trost LW, Gur S, Hellstrom WJ. Pharmacological management of peyronie's disease. Drugs 2007; 67:527-545.
2- Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized doubleblind,
placebo-controlled study. Int J Impot Res 2004;16:238-243.
3- Fitch WP 3rd , Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical trifluoperazine, and topical
magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med 2007; 4:477-
4- Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a
double-blind study. J Urol 1993;149:56-58.
5- Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo
controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive
treatment for Peyronie's disease. J Urol 2006; 176:394.
6- Kelly RB. Pathways of protein secretion in eukaryotes. Science 1985; 230:25-32.
7- Levine LA, Estrad CR. Intralesional disease: a review verapamil for the treatment of Peyronie's. Int J Impot Res
2002; 14: 324-328.
8- Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol
1994; 151: 1522-1524.
9- Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of
three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007; 69:950-954.
10 - Teloken C. Objective evaluation of non-surgical approach for Peyronie's disease. J Urol 1996; 155: 633A, abstract 1290.
11- Arena F, Peracchia G, Di Stefano C, Passari A, Larosa M, Cortellini P. Clinical effects of verapamil in the treatment
of Peyronie's disease]. Acta Biomed Ateneo Parmense 1995; 66:269-272.
12- Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term
single-blind study. Urology 1998; 51:620-626.
13 - Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158:1395-1399.
14- Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease.
J Urol. 2002; 168:621-625; discussion 625-6 Department of Urology, Rush Presbyterian-St. Luke's Medical Center,
Chicago, Illinois, USA
15- Levine LA, Newell MM. FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med
Devices 2008 ;5:305-310.
16- Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease.
Urology 2007; 69:1181-1184.
17- Tunuguntla HS. Management of Peyronie's disease--a review. World J Urol 2001; 19:244-250.
18- Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy
of advanced and resistant Peyronie's disease: BJU Int 2002; 89:895-900.
19- Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's
disease: a double-blind, placebo controlled trial. J Urol 2007; 177:972-975.